@article{article, title  = {{The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial}},

 publisher = {{BMC}},

 url = {{https://eprints.whiterose.ac.uk/id/eprint/142352 https://doi.org/10.1186/s13063-018-2524-8 }},

 year = {{2018}},

 month = {{12}},

 author = {{Striha A and Ashcroft AJ and Hockaday A and Cairns DA and Boardman K and Jacques G and Williams C and Snowden JA and Garg M and Cavenagh J and Yong K et al}},

 doi = {{10.1186/s13063-018-2524-8}},

 volume = {{19}},

 journal = {{Trials}},

 note = {{Accessed on 2025/11/15}}}